HIV medications: an update and review of metabolic complications.
In the past 30 years, medical advances for those with human immunodeficiency virus (HIV) have reduced morbidity and mortality to extend life with highly active antiretroviral therapy (HAART) and with the continued development of new therapies. With this success, HIV is being managed chronically, but other health issues of an aging HIV-infected population have emerged. The challenges of treating HIV infection have shifted from AIDS-related mortality improvements to drug-induced disease from HAART, including cardiovascular disease, metabolic disorders, and bone health. Prolonged use of antiretroviral therapy maintaining immune restoration appears to represent additional, ongoing risk factors for the development of these metabolic complications. These drug-related problems continue to challenge patients and clinicians in the management of HIV disease, as well as ongoing research for drug development improvements to minimize these risks. These health risks imposed by HAART must be vigilantly monitored and aggressively addressed to improve the overall health of those treated for HIV infection.
Auburn University Harrison School of Pharmacy, Auburn University, 1321 Walker Building, Auburn, AL 36849, USA. hesteek@auburn.edu
E Kelly
EK
Hester
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy / Q000821:virology; D019380:Anti-HIV Agents / Q000009:adverse effects*; D001847:Bone Diseases / Q000139:chemically induced*; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000821:virology; D006801:Humans; D008659:Metabolic Diseases / Q000139:chemically induced*
D019380:Anti-HIV Agents